mutation class

Copy Number Variant

A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)

155 sites for NCT03178552

ALK Alternative Transcription Site, +7 more biomarkers

Non-Small Cell Lung Carcinoma

alectinib, +2 more drugs

immunotherapy, +1 more type

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

71 sites for NCT03570892

ALK Alternative Transcription Site, +7 more biomarkers

ALK-Positive Large B-Cell Lymphoma, +13 more conditions

chemotherapy, +1 more drug

cellular therapy, +2 more types

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

24 sites for NCT04644315

ALK Amplification, +2 more biomarkers

Malignant Solid Tumor

alectinib

targeted therapy

A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory PTCL

1 site for NCT05138458

ALK Alternative Transcription Site, +5 more biomarkers

Anaplastic Large Cell Lymphoma, +4 more conditions

lymphodepletion therapy, +1 more drug

chemotherapy, +2 more types

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

35 sites for NCT04591431

AKT1 Amplification, +59 more biomarkers

Malignant Solid Tumor

ado-trastuzumab emtansine, +19 more drugs

immunotherapy, +1 more type

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

1 site for NCT05004116

ALK Amplification, +16 more biomarkers

Desmoplastic Small Round Cell Tumor, +3 more conditions

irinotecan, +2 more drugs

chemotherapy, +1 more type